Portola Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
66.09 M |
Public Float |
56.59 M |
Portola Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$5.18 |
Market Cap |
$1.8 B |
Shares Outstanding |
68.11 M |
Public Float |
63.71 M |
Address |
270 East Grand Avenue South San Francisco California 94080 United States |
Employees | - |
Website | http://www.portola.com |
Updated | 07/08/2019 |
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. |